Seven-year follow-up data show that transcatheter aortic-valve replacement (TAVR) and surgical aortic-valve replacement have ...

A troubling rise in severe diverticulitis cases among Americans under 50 highlights a significant public health concern.

Edwards Lifesciences has raised its fiscal year (FY25) guidance to between $2.56 to $2.62 per share after achieving better ...

Trials from Edwards, Philips and Penumbra were among the most-watched studies at the annual cardiovascular meeting.

Ullem, who has held the post for more than a decade, will transition to an advisory role after his replacement is named by ...

Jefferies and Wolfe Research both upgraded Edwards Lifesciences EW) with Jefferies citing recent strong data for the SAPIEN ...

In ENCIRCLE, TMVR was performed in very ill patients with symptomatic mitral valve disease unsuitable for surgery or commercially available transcatheter edge-to-edge repair (TEER). Given the huge ...

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2025. Recent Highlights. Q3 ...

It’s the height of meeting season! All our most-read stories this month hailed from the news team’s on-site coverage.